Key result
NLRP3 inflammasome activation contributes to AF onset and progression, emerging as a potential therapeutic target.
Why the study?
NLRP3 inflammasome activation has been increasingly implicated in the onset and progression of atrial fibrillation, but its role and therapeutic targeting remain to be comprehensively reviewed.
NLRP3 inflammasome signaling is a key contributor to atrial fibrillation pathogenesis and represents a potential novel therapeutic target.
Answers are grounded in this paper and cite their sources.
Should not change AF practice yet; leaves open NLRP3 targeting for confirmatory clinical trials.
As the most prevalent form of arrhythmia, atrial fibrillation (AF) increases the risk of heart failure, thromboembolism, and stroke, contributing to the raising mortality and morbidity in patients with cardiovascular diseases. Despite the multifaceted nature of AF pathogenesis and complexity of AF pathophysiology, a growing body of evidence indicates that the NLRP3 inflammasome activation contributes to onset and progression of AF. Herein, the authors aim at reviewing the current literature on the role of inflammasome signaling in AF pathogenesis, and novel therapeutic options in the management of AF.
No takes yet. Share an insight, caveat, or question.
Ajoolabady et al. (2022) conducted a review in Atrial fibrillation. Inflammasome signaling was evaluated. A growing body of evidence indicates that NLRP3 inflammasome activation contributes to the onset and progression of atrial fibrillation, highlighting novel therapeutic options for its management.
Synapse has enriched 10 related papers. Consider them for comparative context: